Agreement between Parkinson Disease Home Diary and Observer Assessments before and after Structured Patient Training
Table 1
Demographic and clinical characteristicsa.
Male/female
10 (50%)/10 (50%)
Age, in years
70 (65–77)
Symptom duration, in years
13 (10-16)
Disease duration, in years
11 (9-14)
Months, since initial screening visitb
36 (34–39)
Hoehn and Yahr stages
2 (1-3)
LEDc in initial study
929 (751–1154)
LED in study extension
1058 (737–1233)
MDS-UPDRSd total in initial study
38 (26–55)
Part I
7 (4–11)
Part II
8 (5–11)
Part III
18 (13–24)
Part IV
4 (3–8)
MDS-UPDRS total, in study extension
55 (43–78)
Part I
10 (8–13)
Part II
15 (9–19)
Part III
29 (21–40)
Part IV
5 (3–7)
Duration of motor fluctuations, in months
68 (52–111)
Hypokinetic fluctuations
68 (51–101)
Hyperkinetic fluctuations
63 (56–93)
Motor fluctuation symptoms
Nightly off
12 (60%)
Wearing off
16 (80%)
Delayed on or no on
11 (55%)
On-off phenomena
16 (80%)
Peak dose dyskinesia
12 (60%)
Biphasic dyskinesia
13 (65%)
Off dose dyskinesia
9 (45%)
MoCAe total in initial study
26 (25–28)
Cognitive impairmentf in initial study
Normal cognition
11 (55%)
Mild cognitive impairment
9 (45%)
Dementia
0 (0%)
MoCA total in study extension
27 (25–28)
Cognitive impairment in study extension
Normal cognition
11 (55%)
Mild cognitive impairment
9 (45%)
Dementia
0 (0%)
aData from the patients included in both the earlier validate study and this study extension. Presented as median (IQR: interquartile range) or percentages. bTime passed between the initial screening visit and the study extension screening visit. cLED: levodopa equivalent dose. dMDS-UPDRS: Movement Disorder Society sponsored the revision of the Unified Parkinson Disease Rating Scale. eMoCA: Montreal Cognitive Assessment. fNormal cognition, MoCA >25; mild cognitive impairment; MoCA 21–25; dementia, MoCA<21.
